arrow
B

Barbara Botto

AOU Citta della Salute e della Scienza di Torino
H指数:3
被引数:124

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Biomarkers of Premature Biological Aging in Hodgkin Lymphoma Survivors: Advanced Glycation End Products, Oxidative Stress, Inflammation and Cellular Senescence

霍奇金淋巴瘤幸存者中过早生物衰老的生物标志物:高级糖化终产物、氧化应激、炎症和细胞衰老

2026-11-110
OAAI
RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma

RENOIR三期研究:利妥昔单抗-来那度胺对比利妥昔单抗作为复发/难治性滤泡性淋巴瘤的维持治疗

2026-09-010
PRE
Continuous positive airway pressure as an alternative to deep-inspiration breath holding for mediastinal lymphoma radiotherapy

持续正压通气作为纵隔淋巴瘤放疗中替代深吸气屏气的方法

2026-04-170
OAAI
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients

FIL MCL0208试验中,来那度胺维持治疗与观察在MCL患者自体干细胞移植(ASCT)后的长期结果

2025-03-220
OAAI
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma
2024-03-189
OAAI
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
2023-08-015
OAAI
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
2023-07-278
OAAI
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
2023-04-014
OAAI
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)
2022-11-1713
OAAI
The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi
2022-10-077
PRE
HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience
2022-02-153
OAAI
Correspondence: Mario Levis,; e-mail; mario.levis@unito.it.
2021-11-0920
OAAI
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience
2021-11-017
OAAI
The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of pet-guided treatments (vol 99, pg 277, 2020)
2020-11-210
OAAI
Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study
2019-12-236
PREAI
The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments

晚期霍奇金淋巴瘤患者的经典预后因素在Pet引导治疗时正在失去意义

2019-12-2310
OAAI
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience
2018-04-166
PREAI